Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
23 results
D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab
D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab
D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis
D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic
D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates
D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab
D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results
D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years
D1.369 - Characteristics of patients with severe asthma undergoing biological treatment at a reference center
D1.371 - Dupilumab for the treatment of refractory severe chronic spontaneous urticaria
- D1.323 - Clinical Experience with Lanadelumab for Hereditary Angioedema in Kazakhstan
D3.317 - Moderate-to-severe infections and initial SELENA-SLEDAI correlate with the incidence of flares in patients with Systemic Lupus Erythematosus
D3.322 - Acquired chronic granulomatous disease secondary to myelodysplastic disorder
D3.324 - Mastoiditis as complication of Hyper IgM syndrome
D3.326 - A RARE COEXISTENCE: CARD9 DEFICIENCY AND IgG4-RELATED DISEASE IN A PEDIATRIC PATIENT
D3.327 - Use of C1 Inhibitor Subcutaneously in the United Kingdom
D3.328 - Relapsing COVID-19 pneumonia and Helicobacter cineadi cellulitis in a patient with X-linked agammaglobulinemia
D3.332 - Determination of Reference Intervals for IgG, IgA, and IgM Levels by Age in Healthy Adults
D3.429 - Performance Analysis of Five Large Language Models, Including GPTo1-Preview, On an Allergy and Clinical Immunology Exam
D3.430 - Artificial intelligence Chatbots Can Influence the Decision-Making and Behavior of Patients with Allergies: Results of a Multicenter Evaluation Study
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download